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Down-regulation of hepatic high-density lipoprotein receptor, models of NS, including those induced by puromycin,
SR-B1, in nephrotic syndrome. adriamycin, and passive Heymann nephritis [1–5]. In ad-
Background. Nephrotic syndrome (NS) is a prototype of dition, rats with hereditary analbuminemia and reducedacquired hypercholesterolemia. Hepatic synthesis and removal
plasma oncotic pressure exhibit the same abnormalityof cholesterol play major roles in the regulation of plasma
in the absence of proteinuria [2]. The accumulation ofconcentration of this sterol. Low-density lipoprotein (LDL)
and high-density lipoprotein (HDL) particles are the primary apo A-I–rich HDL in the nephrotic animals is due to
vehicles for cholesterol transport to the liver. We have recently increased hepatic synthesis and diminished catabolism
demonstrated that NS results in acquired hepatic LDL receptor of HDL and its principal apolipoprotein, apo A-I [1, 2].deficiency in rats. This study was undertaken to determine the
Recently, Acton et al isolated and cloned a cell mem-effect of NS on hepatic expression of the newly discovered,
brane-associated protein that exhibited high binding af-long-sought HDL receptor.
Methods. Hepatic HDL receptor and apolipoprotein A-I finity for HDL [6, 7]. The protein was found to be heavily
(apo A-I) expressions were studied in rats with puromycin- expressed by the liver and nonplacental steroidogenic
induced NS. The results were compared with those obtained
tissues, namely, the adrenal glands, testes, and ovaries.in placebo-treated, normal controls.
The authors identified this protein as a scavenger recep-Results. The NS group exhibited a marked reduction in he-
patic tissue HDL receptor protein abundance when compared tor class B, type 1 (SR-B1) molecule. Based on its high
with the control group. In contrast, hepatic HDL receptor binding affinity for HDL, the protein was identified as
mRNA abundance in the NS group was similar to that of the the long-sought HDL receptor [6, 7].
control group. As expected, the NS group showed a marked
In view of these considerations, it is conceivable thatincrease in hepatic apo A-I mRNA abundance.
alterations in HDL receptor expression might lead toConclusions. The study explored the effect of experimental
NS on hepatic HDL receptor expression, and the results re- significant changes in plasma cholesterol concentration
vealed a marked down-regulation of HDL receptor in rats with and quantitative and compositional modifications of
NS. In contrast, hepatic expression of Apo A-I, the principal HDL. We therefore considered that nephrotic hypercho-protein constituent of HDL, was markedly increased in NS
lesterolemia and HDL abnormalities may be in part in-rats. The HDL receptor deficiency shown here can potentially
dicative of impaired HDL receptor expression. To ex-limit the efficiency of HDL as the primary vehicle for reverse
cholesterol transport in NS. plore this possibility, we examined expression of this
novel receptor in the liver of nephrotic and control ani-
mals. The study revealed a marked reduction in hepatic
Hyperlipidemia is one of the cardinal manifestations HDL receptor protein expression in rats with experimen-
of nephrotic syndrome (NS). Elevation of the serum tal nephrosis.
cholesterol concentration in rats with experimental NS
is accompanied by a marked rise in plasma high-density
METHODSlipoprotein (HDL) concentration and apolipoprotein
Study groupsA-I (apo A-I) enrichment of HDL particles. This phe-
nomenon is consistently observed in all experimental Male Sprague-Dawley rats (Charles River Inc., Wil-
mington, MA, USA) weighing 180 to 200 g were housed
in a temperature- and light-controlled space with 12-Key words: proteinuria, hyperlipidemia, scavenger receptor, choles-
terol, apolipoprotein A-I, lipids. hour light (500 lux) and 12-hour dark (#5 lux) cycles.
The rats were allowed free access to food (Purina RatReceived for publication March 9, 1998
Chow; Purina Mills Inc., Brentwood, MO, USA) andand in revised form February 19, 1999
Accepted for publication March 13, 1999 water. Animals were randomized into the NS and normal
control groups. The rats assigned to the NS group re- 1999 by the International Society of Nephrology
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ceived sequential intraperitoneal injections of puromy- in 2.2 m formaldehyde at 658C for 15 minutes and run
on 1.0% agrose/2.2 m formaldehyde gel at 46 V for sevencin aminonucleoside on day 0 (130 mg/kg) and day 14
(60 mg/kg). The rats assigned to the control group instead hours. The separated RNA was transferred to the nylon
membrane (Zeta Probe; Bio-Rad) by capillary blottingreceived placebo injections of 5% dextrose in water.
Subgroups of animals were killed 24 hours, 14 days, and in 6 3 standard saline citrate (SSC) buffer overnight
and immobilized by ultraviolet irradiation (Ultraviolet30 days after the initial puromycin or placebo injections.
A minimum of six animals were used in each subgroup. Crosslinker; Fisher Scientific, Pittsburgh, PA, USA). The
membrane was incubated at 658C in a solution containingPrior to sacrifice, the animals were placed in individual
metabolic cages for a timed urine collection. Under so- 5 3 SSPE (sodium chloride, sodium phosphate, EDTA
buffer), 5 3 Denhardt’s, 1% sodium dodecyl sulfatedium pentobarbital anesthesia (50 mg/kg, intraperitone-
ally), the animals were sacrificed, and the liver was imme- (SDS), and 100 mg/ml salmon sperm DNA for four hours.
The cDNA probe for human b-actin (1.1 kb Eco/RIdiately removed, frozen in liquid nitrogen, and stored at
2708C until processed. In addition, blood was collected fragment) and the cDNA probe for human apo A-I (0.6
kb Pst I fragment) were obtained from American Typeusing cardiac puncture. Twenty-four–hour urinary pro-
tein excretion, creatinine clearance, and plasma concen- Culture Collection (Rockville, MD, USA). The cDNA
probe for the HDL receptor was prepared as describedtrations of total cholesterol, triglycerides, HDL choles-
terol, albumin, and creatinine were determined using earlier here. The probes were labeled with [32P] dCTP
(3000 Ci/mmol; New England Nuclear Inc., Boston, MA,standard laboratory techniques.
USA) by the random primer method (Promega Inc.,
Polymerase chain reaction Madison, WI, USA). Hybridization was carried out at
658C in a prehybridization solution with 32P-labeledPolymerase chain reaction (PCR) was used to produce
a partial cDNA probe for rat HDL receptor using the cDNA. The blots were washed twice in 2 3 SSPE/0.5%
SDS solution at room temperature, twice in 1 3 SSPE/following primers: HDL-R1, 59 GTC AGC ACC TGC
AGG TTT GG, and HDL-R2, 59 TTT CTC CTG GCT 0.5% SDS solution at 378C, and twice in 0.1 3 SSPE/
0.5% SDS solution at 658C for 15 minutes each. TheGCG CAG TTG. The nucleotide compositions of these
primers were derived from a previously published HDL washed blots were exposed to x-ray film (New England
Nuclear Inc.) at 2808C for two to six hours for actin andreceptor sequence [6]. These primers were used to am-
plify a 417 bp rat HDL receptor cDNA fragment. First- five days for HDL receptor and apo A-I. The audio-
graphs were scanned with a laser densitometer (Molecu-strand cDNA was synthesized from 1 mg rat liver cDNA
library employing a cDNA cyclic kit (Invitrogene, San lar Dynamics, Sunnyvale, CA, USA) to determine rela-
tive mRNA levels. The values obtained for constitutivelyDiego, CA, USA). The cDNA was then amplified by
PCR in 50 ml of a solution containing 10 mm Tris-HCl, expressed actin gene were used as an internal control.
50 mm KCl, 1.5 mm MgCl2, 200 mm dNTP mixture, 1 U
Western blot analysisTaq polymerase, and 1 mm of each primer. PCR amplifi-
cation was carried out for 30 cycles. Each cycle included These measurements were carried out to determine
the HDL receptor protein mass. To this end, hepatocytethe following steps: 948C, 558C, and 728C for one minute
each. The PCR products were separated on 1% agarose plasma membranes were prepared and processed as pre-
viously described [9]. In brief, frozen rat liver was ho-gel, and the band corresponding to the 400 base pairs
was cut, isolated with a Gene-CleanII Kit (Qiagen Inc., mogenized in 1 ml of 20 mm Tris-HCl (pH 7.5) buffer
containing 2 mm MgCl2, 0.2 m sucrose, 5 mm phenylmeth-Chatsworth, CA, USA), and then ligated to a PCRII
vector using a TA cloning kit (Invitrogene). A positive ylsulfonyl fluoride, 5 mg/ml leupeptin, 10 mg/ml aprotinin,
and 3 mg/ml pepstatin A. The crude extract was centri-insert was sequenced by Sequenase Version 2.0 Kit
(United States Biochemical Co., Cleveland, OH, USA) fuged at 3000 g for 10 minutes at 48C to remove the
debris. The supernatant was then centrifuged at 35,000 gon double-stranded DNA. To prepare the probe, an ap-
proximate 0.4 kb HDL receptor cDNA insert was excised for 30 minutes to sediment the membrane fractions. The
membrane preparation was then washed with the pre-by EcoRI from the previously mentioned clone.
viously mentioned buffer and centrifuged at 35,000 g for
RNA preparation and Northern blot analysis 45 minutes at 48C. Protein concentration was determined
by means of a Bio-Rad kit (Bio-Rad Laboratories). Ali-Total RNA was prepared from 0.25 g liver with RNA-
zol using the manufacturer’s recommended procedure quots containing 25 mg of protein were size fractionated
on 4 to 20% Tris-glycine gel (Novex Inc., San Diego,(Tel-Test Inc., Friendswood, TX, USA) as previously
described [8]. The RNA concentration was determined CA, USA) at 120 V for two hours. After electrophoresis,
proteins were transferred to Hybond-ECL membranefrom the absorbance at 260 nm using a spectrophotome-
ter (Gene-Quat; Bio-Rad, Hercules, CA, USA). Twenty- (Amersham Life Science Inc., Arlington Heights, IL,
USA). The membrane was incubated for one hour infive microgram aliquots of total RNA were denatured
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Table 1. Plasma concentrations of total cholesterol, high density lipoprotein (HDL)-cholesterol, triglycerides, albumin and creatinine as
well as 24-hour urinary protein excretion and creatinine clearance (CCr) in the normal control group, pre-nephrotic animals studied
24 hours after puromycin injection, and the nephrotic group
P values
Normal Pre-nephrotic Nephrotic (ANOVA)
Total cholesterol mg/dl 70.263.2 71.2 63.1 275.4618.2 ,0.001
HDL-cholesterol mg/dl 27.563.8 28.5 63.5 46.566.0 ,0.01
Triglyceride mg/dl 46.166.8 45.2 65.2 224.3624.1 ,0.001
Albumin g/dl 3.7660.1 3.68 60.2 2.7960.1 ,0.01
Creatinine mg/dl 0.6560.05 0.58 60.02 0.5660.08 NS
CCr ml/min 1.2460.1 1.21 60.1 1.3260.1 NS
Urine protein mg/24hrs 7.060.9 7.2 60.7 267.4619.5 ,0.01
buffer A [1 3 phosphate-buffered saline (PBS), 0.1%
Tween-20, and 5% nonfat milk] and then overnight in the
same buffer containing 1:3000 polyclonal HDL receptor
antibody (SR-B1; Novus Biologicals Inc., Littleton, CO,
USA). The membrane was washed once for 15 minutes
and then twice for 5 minutes in 1 3 PBS, 0.1% Tween-20
prior to a two-hour incubation in buffer A plus diluted
(1:3000) horseradish peroxidase-linked antirabbit IgG
(Amersham Life Science). The washes were repeated
before the membranes were developed with chemilumi-
nescent agents (ECL; Amersham Life Science) and sub-
jected to autoluminography for 15 seconds.
Data presentation and analysis
Analysis of variance, Student’s t-test, and regression
analysis were used in statistical evaluation of the data.
Data are presented as mean 6 sem. P values equal to
or less than 0.05 were considered significant.
RESULTS
General data
As expected, the NS group exhibited marked protein-
uria and hypoalbuminemia. No significant difference was
found in either serum creatinine concentration or creati-
nine clearance between the NS and the control groups.
Thus, the NS group had nephrotic proteinuria without Fig. 1. (Upper panel ) Representative Western blot of HDL receptor
(HDLR) protein obtained in a placebo-treated rat (NL), a pre-nephroticrenal insufficiency. In comparison with the control group,
rat studied 24 hours after puromycin aminonucleoside (PAN) injectionthe NS group exhibited marked elevations of plasma (D1), and the nephrotic animals studied on days 14 (D14) and 30 (D30)
after initial PAN injection. (Lower panel ) Group data reflecting relativetotal cholesterol, triglycerides, low-density lipoprotein
optical densities of HDLR protein bands in the corresponding sub-(LDL) cholesterol, and HDL cholesterol. There was no
groups. N 5 6 in each subgroup. *P , 0.01 vs. vales found in NL and
significant change in any of these parameters in pre- D1 subgroups.
nephrotic animals studied 24 hours after puromycin in-
jection (Table 1).
and 30 (Fig. 1). Hepatic HDL receptor protein abun-
High-density lipoprotein receptor expression dance was inversely related to the degree of proteinuria
The nephrotic group exhibited a significant reduction (r 5 20.88, P , 0.01) and directly related to serum
albumin concentration (r 5 0.81, P , 0.01). In contrastin hepatic HDL receptor protein expression at days 14
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Fig. 3. (Upper panel ) Representative Northern blots of hepatic apoFig. 2. (Upper panel ) Representative Northern blot of hepatic HDL
A-I mRNA and actin mRNA in two nephrotic (NS) and two normalreceptor (HDL-R) mRNA and the corresponding actin mRNA in two
control (NL) animals studied 30 days after the initial injections ofnephrotic rats (NS) and two normal control rats (NL) studied 30 days
puromycin and placebo, respectively. (Lower panel ) Group data de-after initial injections of puromycin aminonucleoside (PAN) or placebo,
picting hepatic apo A-I/actin mRNA in nephrotic rats (NS) studied 30respectively. (Lower panel ) Group data illustrating the hepatic HDL-
days after initial injections of puromycin (N 5 6) and normal controlsreceptor/actin mRNA in six nephrotic (NS) and six normal control
(NL) studied 30 days after placebo injections (N 5 6). *P , 0.01.(NL) rats obtained 30 days after initial injections of PAN and placebo,
respectively. No significant difference was observed between the two
groups.
Effect of puromycin
Hepatic apo A-I and HDL receptor expressions were
to HDL receptor protein, hepatic tissue HDL receptor unchanged in prenephrotic animals studied 24 hours
mRNA abundance was normal in the NS group (Fig. 2). after puromycin injection, at which time proteinuria was
It thus appears that down-regulation of hepatic HDL absent (Fig. 4). This observation argues against an effect
receptor expression in NS occurs at the level of protein, of puromycin per se on hepatic expressions of either apo
as opposed to mRNA. Interestingly, NS affects hepatic A-I or HDL receptor.
LDL receptor in a precisely similar manner [9].
DISCUSSION
Apolipoprotein A-I expression
The nephrotic animals employed in this study exhib-
The NS group exhibited a marked increase in hepatic ited a marked elevation of plasma HDL concentration.
apo A-I mRNA abundance (Fig. 3), confirming earlier This was accompanied by increased hepatic apo A-I
studies in this and other models of NS [1, 2]. There mRNA abundance. These findings are consistent with
was a significant direct correlation between plasma HDL the results of the earlier studies of rats with NS induced
cholesterol concentration and hepatic apo A-I mRNA by Heymann nephritis [2], adriamycin [1, 2], and puromy-
abundance in the study population (r 5 0.78, P , 0.05). cin [3, 4]. Increased hepatic tissue apo A-I mRNA abun-
This observation suggests that the increased plasma dance shown in this and other studies in various models
HDL concentration in the NS rats is, at least in part, of NS points to its increased production as a cause of
due to enhanced hepatic production of apo A-I, as shown elevated plasma Apo A-I and HDL levels in the ne-
phrotic rats. In fact, Sun et al have demonstrated a sig-by other investigators [1–5].
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apo A-I is not reduced in the nephrotic humans. In fact,
the fractional apo A-I catabolic rate was increased in
two NS patients reported by Saku et al [11]. This is because
NS increases the amount of cholesteryl ester transfer
protein (CETP) in humans [12]. However, this protein
is absent in the rat [13]. By transferring cholesteryl ester
core of HDL2 particles to very low-density lipoprotein
(VLDL), CETP facilitates conversion of the larger HDL2
to the smaller HDL3 particles, which have less affinity
for apo A-I than the HDL2 [14]. Thus, increased CETP in
nephrotic humans helps to reduce apo A-I incorporation
into HDL and, as such, facilitates clearance/catabolism
of this small molecular size protein (23 kD) in the kidney.
This viewpoint is supported by the observation that apo
A-I catabolism is reduced and that plasma apo A-I, apo
A-II, and HDL cholesterol concentrations are increased
in humans with hereditary CETP deficiency [15]. As a
result of enhanced apo A-I catabolism occasioned by
increased CETP, plasma apo A-I and HDL cholesterol
concentrations are frequently unchanged or even re-
duced in nephrotic patients, contrasting their frequent
elevation in the nephrotic rats that lack CETP.
Apo A-I is produced in the liver and intestine and is
primarily catabolized in the liver and the kidney and to
a lesser extent in other tissues, including the skin, spleen,
gonads, and adrenal glands [16]. The concentration of
HDL in plasma is dependent on the rates of synthesis
and catabolism of its apoprotein and lipid constituents.
As noted earlier in this article, synthesis of the HDL’s
principal apoprotein, apo A-I, is increased, whereas the
rate of its catabolism is decreased in nephrotic rats. HDL
plays an important role in reverse transport of choles-
terol from the extrahepatic tissues to the liver. In addi-
tion, HDL is involved in the delivery of cholesteryl esters
Fig. 4. (A) Hepatic apo A-I/actin mRNA (ratio). (B) Hepatic high-
to nonplacental steroidogenic tissues, including the tes-density lipoprotein (HDL) receptor/actin mRNA (ratio) in rats studied
24 hours after intraperitoneal injections of puromycin aminonucleoside, tes, ovaries, and adrenal glands. Until recently, the pre-
130 mg/kg (PAN), or vehicle (NL) alone. No significant difference was cise mechanism of cholesterol uptake from HDL by liver
observed between the two subgroups. N 5 6 in each subgroup.
and the steroidogenic glands was unknown. However,
the issue has been substantially clarified by the recent
discovery of the HDL receptor, which is abundantly ex-
pressed in the liver, adrenal glands, testes, and ovariesnificant increase in hepatic apo A-I transcription rate in
rats with experimental nephrosis [2]. [6, 7]. The HDL receptor was recently identified by Ac-
ton et al as a SR-B1 molecule [6, 7]. It is a cell membrane-Recently, Kaysen, Hoye, and Jones have demon-
strated a significant reduction in apo A-I catabolism in associated protein with high affinity for HDL. Cells
transfected with HDL receptor gene exhibit a strongnephrotic rats with Heymann nephritis, despite signifi-
cant urinary losses of this protein [1]. Similarly, Sparks, saturable binding affinity for HDL. HDL binding to its
receptors on transfected cells results in removal and in-Tennenberg, and Marsh demonstrated a marked reduc-
tion in fractional catabolic rates of all apolipoprotein ternalization of cholesterol without degradation or up-
take of the HDL apoprotein constituents [6, 7]. Thus,constituents of HDL in rats with puromycin-induced NS
[10]. These findings reveal another mechanism for accu- the HDL receptor serves as a docking receptor for HDL,
which operates as a recycling shuttle for cholesterol de-mulation of apo A-I–rich HDL in rats with NS. Thus,
the combination of increased synthesis and depressed livery from the peripheral tissues to the liver and ste-
roidogenic glands. In this regard, the HDL receptor iscatabolism of apo A-I serves to raise its plasma concen-
tration in the nephrotic rats. It should be noted that distinctly different from the LDL receptor, which oper-
ates by internalization and removal of the whole LDLunlike the nephrotic rats, the fractional catabolism of
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